Cathie Wood pours $19.2 million on biotech stock, trims favorite

Love her or roll your eyes, Cathie Wood’s bets are virtually impossible for investors to miss.

With clear theses and gutsy bets early on, the ARK Invest boss is willing to flip the script when the facts change. 

That playbook proved remarkably effective this year, with ARK Innovation ETF (ARKK) stock up 58% year to date, blowing past broader benchmarks while drawing fresh attention to “disruptive innovation.”

Lately, she’s been laser-focused on the next leg of the cycle. 

So far, it has been biotech stocks with real catalysts on the horizon, along with AI-adjacent platforms where data, payments, and e-commerce intersect. 

Behind the scenes, Wood is tilting the portfolio to effectively reflect that view. In her latest portfolio reshuffling, we can spot outlines in a couple of places in particular. 

The first includes selective adds where science or software is nearing an inflection point, along with measured trims where multiples ran quicker than fundamentals.

The moves imply a methodical reweighting toward what could potentially matter the most in the back half of this year.

Cathie Wood cuts Shopify stake, piles into Intellia and Block

Cathie Wood just sent a clear signal with her moves, with her looking to trim stretched winners while doubling down on what comes next.

The ARK Invest founder just made arguably her largest biotech bets of 2025, picking up a remarkable 750,000 shares of Intellia Therapeutics (NTLA) worth $19.2 million. 

For some color, the popular gene-editing player is focused on CRISPR therapies for ATTR amyloidosis (NTLA-2001) and hereditary angioedema (NTLA-2002). These programs are being billed as transformative “one-and-done” treatments for high-value rare diseases. 

With key data milestones ahead, Wood is positioning for a biotech re-rating that could potentially unfold over the next year.

Fund manager buys and sells:

• Cathie Wood drops $12 million on resurgent tech giant
• Cathie Wood sells shares in major AI stock
• Why 2 major asset managers just suspended investments into silver

Her appetite for innovation didn’t stop there. 

ARK also made a sizeable $30.7 million investment in Block, scooping up a healthy 385,585 shares across ARKK, ARKW, and ARKF. 

The outsized bet underscores Wood’s conviction in fintech infrastructure, with AI and payments converging. 

On top of that, smaller and relatively strategic additions followed. 

ARK added 268,833 DraftKings shares worth $8.9 million, 17,579 Amazon shares valued at $3.9 million, and 14,881 Alibaba shares worth a hefty $2.6 million. It also grew its genomic footprint, adding 562,505 Pacific Biosciences stock and 274,939 10x Genomics shares.

Related: JPMorgan revamps Google stock target on quiet game-changer

On the flip side, Wood surprised one and all by trimming a few longtime favorites. Shopify (SHOP) was ARK’s largest sale, offloading 281,738 shares worth $48.7 million.

For perspective, Shopify’s Q2 sales jumped 31% to $2.68 billion, while GMV hit $87.8 billion, and free-cash-flow margins hovered near 16%, with rising costs and a cautious profit outlook prompting trims.

Also, ARK sold 139,222 shares of Palantir, 50,832 shares of Roblox, along with smaller cuts to Ionis Pharmaceuticals and Iridium Communications.

Cathie Wood's buys

• Intellia Therapeutics: +750,000 shares, $19.2 million
• Block: +385,585 shares, $30.7 million
• DraftKings: +268,833 shares, $8.9 million
• Amazon: +17,579 shares, $3.9 million
• Alibaba: +14,881 shares, $2.6 million
• Pacific Biosciences: +562,505 shares
• 10x Genomics: +274,939 shares

Wood's sells

• Shopify: -281,738 shares, $48.7 million
• Palantir: -139,222 shares, $4.1 million
• Roblox: -50,832 shares
• Ionis Pharmaceuticals: Reduced position
• Iridium Communications: Reduced position 

Cathie Wood warns of an AI "reality check" as valuations soar

Cathie Wood isn’t calling out an AI bubble as yet, but she’s clearly flashing a caution light.

Speaking at Saudi Arabia’s Future Investment Initiative in Riyadh, the ARK Invest CEO said, despite being bullish on AI and its long-term impact, AI valuations could potentially face a “reality check.”

Related: Palantir quietly makes massive AI war play

Her warning comes at a time when investors continue to pour billions into tech giants and AI-powered names, including AMD, Nvidia, Palantir, and others, pushing the red-hot sector to frothy highs.

Wood feels that investors misunderstand the relationship between innovation and interest rates, noting that they are “not inversely correlated over history.”

These comments come as a relative surprise, considering that ARK’s own innovation funds in ARKK, ARKW, and ARKF continue rallying hard this year, led by healthy exposure to AI-linked names.

Still, Wood’s message to investors is clear: The next 12 months could test just how much of the AI boom is priced in at this time.

Related: Top analyst calls 'kick in the pants' for S&P 500